Clinical Trials in Nashville

Showing 841-860 of 9,711 trials

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

NCT07195916

A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

Solid TumorsHematologic Malignancies

Incyte Corporation280 participantsStarted Jan 2026

Duarte, California, United States • La Jolla, California, United States • Ann Arbor, Michigan, United States +19 more locations

ACTIVE_NOT_RECRUITINGPHASE1/PHASE2< 1 mile

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

NCT04072952

This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and anti-tumor activity of ARV-471 alone and in combination with palbociclib (IBRANCE®) in patients with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer, who have received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting.

Breast Cancer

Arvinas Estrogen Receptor, Inc.217 participantsStarted Aug 2019

Palo Alto, California, United States • San Francisco, California, United States • Santa Monica, California, United States +13 more locations

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Find Trials by Condition in Nashville

Amplatzer Amulet LAAO vs. NOAC

Study of INCB123667 in Subjects With Advanced Solid Tumors

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

A Study of Barzolvolimab in Patients With Atopic Dermatitis

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)

A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma

A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Maternal-fetal Immune Responses to Fetal Surgery

Intratumoral PH-762 for Cutaneous Carcinoma

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

Study of ATX-01 in Participants With DM1

FdCyd and THU for Advanced Solid Tumors

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Coin2Dose: Behavioral Economics to Promote Insulin BOLUS Activity and Improve HbA1c in Teens

Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations

EMUs: Enhanced Monitoring Using Sensors After Surgery